Skip to content
  • Categories
  • Recent
  • Tags
  • Popular
  • Users
  • Groups
Skins
  • Light
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Collapse
Brand Logo

Forum

  1. Home
  2. PAAB Q&A
  3. Claims & Support/References for Claims
  4. Secondary hierarchical endpoints
PAAB Notice
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB), including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.

Secondary hierarchical endpoints

Scheduled Pinned Locked Moved Claims & Support/References for Claims
4 Posts 2 Posters 369 Views
  • Oldest to Newest
  • Newest to Oldest
  • Most Votes
Reply
  • Reply as topic
Log in to reply
This topic has been deleted. Only users with topic management privileges can see it.
  • U Offline
    U Offline
    Username
    wrote on last edited by
    #1

    Hello,
    If a pivotal trial has a secondary endpoint that is predefined and included in the trial description in the monograph, but the data is not included in the monograph due to a failed secondary endpoint higher up in the hierarchical testing structure, is it possible to present the data for this endpoint in a neutral way in an APS (knowing that significance could NOT be claimed for this endpoint)?

    Jennifer CarrollJ 1 Reply Last reply
    0
    • U Username

      Hello,
      If a pivotal trial has a secondary endpoint that is predefined and included in the trial description in the monograph, but the data is not included in the monograph due to a failed secondary endpoint higher up in the hierarchical testing structure, is it possible to present the data for this endpoint in a neutral way in an APS (knowing that significance could NOT be claimed for this endpoint)?

      Jennifer CarrollJ Offline
      Jennifer CarrollJ Offline
      Jennifer Carroll
      wrote on last edited by
      #2

      Hello @username

      Listing the outcomes within the trial design in the TMA does not necessarily qualify it for discussion within a promotional tool. As a general rule of thumb, if there are no valid stats, there is no claim. Data for endpoints past the failed endpoint in hierarchical testing, should not be presented in advertising.

      U 1 Reply Last reply
      0
      • Jennifer CarrollJ Jennifer Carroll

        Hello @username

        Listing the outcomes within the trial design in the TMA does not necessarily qualify it for discussion within a promotional tool. As a general rule of thumb, if there are no valid stats, there is no claim. Data for endpoints past the failed endpoint in hierarchical testing, should not be presented in advertising.

        U Offline
        U Offline
        Username
        wrote on last edited by
        #3

        @jennifer-carroll Thank you for your quick reply. Would it be acceptable to disclose this endpoint in an APS when discussing study design, as it would be consistent with the TMA?

        Jennifer CarrollJ 1 Reply Last reply
        0
        • U Username

          @jennifer-carroll Thank you for your quick reply. Would it be acceptable to disclose this endpoint in an APS when discussing study design, as it would be consistent with the TMA?

          Jennifer CarrollJ Offline
          Jennifer CarrollJ Offline
          Jennifer Carroll
          wrote on last edited by
          #4

          Hey @username

          In the context of a study design, with no additional weight that would emphasize the endpoint, it would likely be acceptable to mention the endpoint.

          1 Reply Last reply
          0
          Reply
          • Reply as topic
          Log in to reply
          • Oldest to Newest
          • Newest to Oldest
          • Most Votes


          • Login

          • Don't have an account? Register

          • Login or register to search.
          • First post
            Last post
          0
          • Categories
          • Recent
          • Tags
          • Popular
          • Users
          • Groups